Incretin therapies have received much attention because of their tissue-protective effects, which extend beyond those associated with glycemic control. Cancer is a primary cause of death in patients who have diabetes mellitus. We previously reported antiprostate cancer effects of the glucagonlike peptide-1 (GLP-1) receptor (GLP-1R) agonist exendin-4 (Ex-4). Breast cancer is one of the most common cancers in female patients who have type 2 diabetes mellitus and obesity. Thus, we examined whether GLP-1 action could attenuate breast cancer. GLP-1R was expressed in human breast cancer tissue and MCF-7, MDA-MB-231, and KPL-1 cell lines. We found that 0.1 to 10 nM Ex-4 significantly decreased the number of breast cancer cells in a dose-dependent manner. Although Ex-4 did not induce apoptosis, it attenuated breast cancer cell proliferation significantly and dosedependently. However, the dipeptidyl peptidase-4 inhibitor linagliptin did not affect breast cancer cell proliferation. When MCF-7 cells were transplanted into athymic mice, Ex-4 decreased MCF-7 tumor size in vivo. Ki67 immunohistochemistry revealed that breast cancer cell proliferation was significantly reduced in tumors extracted from Ex-4-treated mice. In MCF-7 cells, Ex-4 significantly inhibited nuclear factor kB (NF-kB ) nuclear translocation and target gene expression. Furthermore, Ex-4 decreased both Akt and IkB phosphorylation. These results suggest that GLP-1 could attenuate breast cancer cell proliferation via activation of GLP-1R and subsequent inhibition of NF-kB activation. (Endocrinology 158: 4218-4232, 2017) 
I
ncretin therapies, which include dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide-1 (GLP-1) receptor (GLP-1R) agonists, have become popular treatments for type 2 diabetes mellitus (T2DM). Recently, incretin therapies have garnered significant attention because of their reported tissue-protective effects, which go beyond the benefits associated with reducing blood glucose (1) . Patients who have diabetes mellitus have a higher risk of cardiovascular events than individuals without diabetes mellitus (2) and frequently experience restenosis after coronary angioplasty, even if intervention was performed with currently established drug-eluting stents (3) . Accordingly, the potential of incretin-related antidiabetic agents to benefit not only glycemic control but also the cardiovascular system has been investigated. We previously demonstrated vascular-protective effects of exendin-4 (Ex-4), a GLP-1R agonist, which included attenuation of atheroma formation in apoE 2/2 mice (4) and reduction in intimal thickening after vascular injury (5) . Thus, incretin therapies could improve quality of life and reduce mortality rates among patients who have diabetes via vascular-protective effects.
Cancer is emerging as a major cause of death in patients who have diabetes mellitus (6) . Notably, in Japan, cancer is the leading cause of death in patients with T2DM (7) . The Japan Diabetes Society and Japan Cancer Association have therefore issued a warning regarding increased cancer risk in patients who have diabetes (8) . Furthermore, a study by Hirakawa et al. (9) suggested that not only diabetes, but also impaired glucose tolerance, increases the incidence of cancer-related deaths in the Japanese population. Specifically, diabetes and metabolic syndrome have been suggested to be associated with a higher risk of many cancers (10) .
We previously demonstrated antiprostate cancer effects of Ex-4 that occurred via inhibition of extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) phosphorylation both in vivo and in vitro (11) . Additionally, we observed a further reduction in tumor size and prostate cancer cell proliferation with combined Ex-4 and metformin therapy (12) , independent of the glucose-lowering effect of this treatment. Although several reports have examined the effect of GLP-1 action on several types of cancers (13) , the precise effect and mechanism of GLP-1 action on breast cancer remain unclear. Breast cancer is a major cancer in women, especially in western countries, and is accelerated in female patients who have diabetes mellitus. It has been reported that women with T2DM have a 1.2-fold higher risk of breast cancer than women without T2DM (14) . In the current study, we examined the anticancer effect of the antidiabetic GLP-1R agonist Ex-4, using a breast cancer model. We revealed that Ex-4 attenuated breast cancer growth by inhibiting nuclear factor kB (NF-kB) activation. Thus, Ex-4 has benefits in addition to its glucoselowering effect.
Materials and Methods

Human tissues
Human breast cancer tissues were obtained from three nondiabetic patients who had breast cancer (one aged 34 years and two aged 57 years) after mammary gland resection at Fukuoka University Hospital. The tissues were paraffinembedded, formalin-fixed, and cut into 3-mm sections for immunofluorescence staining. Two sections were cut and stained from each of three independent breast cancers from the three independent patients. The study protocol was approved by the Ethics Committees of Fukuoka University Hospital.
Cell culture and cell proliferation assays
The MCF-7 and MDA-MB-231 human breast cancer cell lines and the LNCaP human prostate cancer cell line were purchased from the American Type Culture Collection (Manassas, VA). The KPL-1 human breast cancer cell line was kindly provided by Dr. Junichi Kurebayashi, Kawasaki Medical School (15) . All breast cancer cells were maintained in Dulbecco's modified Eagle medium (DMEM), and LNCaP cells were maintained in Roswell Park Memorial Institute 1640 medium. All media were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cell proliferation assays were performed as described previously (11) with minor modifications. Briefly, cells were seeded in 12-well tissue culture plates and maintained in complete media with or without 0.1 to 10 nM Ex-4 or 100 nM exendin (9-39) (Sigma-Aldrich, St. Louis, MO), and with or without 0.1 to 10 nM linagliptin (kindly provided by Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany). Cell proliferation was analyzed after 0 to 3 days or 48 hours after by cell counting using a hemocytometer.
Construction of GLP-1R-expressing lentiviral vectors and viral transduction
We constructed lentiviral vectors including a Flag epitope tag. A SpeI-and ScaI-treated pCR-GLP-1R fragment was subcloned into a SpeI-and ScaI-treated pFLAG CMV-2 expression vector (catalog no. E7033; Sigma-Aldrich). DNA encoding Flag-GLP-1R was subcloned into XbaI-and NotItreated pLVSIN-EF1a (catalog no. 6186; Clontech, Mountain View, CA). A lentiviral vector containing Flag-GLP-1R was generated by transfecting HEK293 cells (catalog no. 631152; Clontech). To upregulate GLP-1R overexpression, we infected MCF-7 cells with pLVSIN-EF1a-Flag GLP-1R at a multiplicity of infection of 10. Three days after transduction, cells were selected and cultured with puromycin in DMEM supplemented with 10% bovine serum albumin for~7 days.
Animals
Female athymic CAnN.Cg-Foxn1nu/CrlCrlj mice were purchased from Charles River Laboratories Japan, Inc., and housed in specific pathogen-free barrier facilities at Fukuoka University. Mice were treated with either saline (control, n = 10) or 300 pmol/kg body weight/d Ex-4 (Sigma-Aldrich, Tokyo, Japan) (n = 10) through a mini-osmotic pump (ALZEST, model 1004; DURECT, Cupertino, CA) for 9 weeks. A second group of mice were treated with saline (n = 5), 300 pmol/kg body weight/d Ex-4 (n = 5), 3 nmol/kg body weight/d exendin at (n = 5), or combined Ex-4 and exendin (9-39) (n = 5) through a mini-osmotic pump for 6 weeks. When the mice reached 6 weeks of age, 1 3 10 6 or 2 3 10 6 MCF-7 cells (passage 4 to 8) were mixed with 250 mL Matrigel (Becton Dickinson Labware, Bedford, MA) and transplanted subcutaneously in the flank region. The osmotic pump was transplanted under the skin of the back of each mouse under local anesthesia, as described previously (11, 12) . When the mice reached 12 or 15 weeks of age, blood samples were collected, and the mice were euthanized. Tumor volume was calculated with the modified ellipsoid formula: length 3 width 2 3 0.52, and paraffin-embedded formalin-fixed tumors were cut into 5-mm sections and prepared for immunofluorescence staining. All procedures involving animals were reviewed and approved by the institutional Animal Care subcommittee at Fukuoka University Hospital.
Reverse transcription and quantitative real-time polymerase chain reaction Reverse transcription (RT) and quantitative real-time polymerase chain reaction (PCR) were performed as described previously (11) . Total messenger RNA (mRNA) from breast cancer cells was isolated using RNeasy Mini Kits (Qiagen, Venlo, the Netherlands) and reverse-transcribed into complementary DNA. PCR reactions were performed using a Light Cycler 2.0 (Roche, Basel, Switzerland) and SYBR Premix Ex Taq™ II (Takara, Otsu, Japan). Each sample was analyzed in triplicate and normalized against TATA-binding protein (TBP) mRNA expression. The primer sequences used were as follows:
To verify human GLP-1R mRNA expression, we also amplified the 890-base pair coding sequence of human GLP-1R using reverse transcription PCR (RT-PCR), as previously reported (11) . PCR products were separated by agarose gel electrophoresis and visualized with ethidium bromide staining.
Hematoxylin and eosin staining
The tissue sections were deparaffinized and rehydrated. The sections were stained in hematoxylin (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 5 minutes, and washed in running water for 15 minutes. Then, the sections were stained with eosin (Muto Pure Chemicals Co., Ltd.) for 3 minutes, dehydrated, and mounted by routine methods.
Immunohistochemistry
Paraffin sections were incubated with anti-GLP-1R (catalog no. NBP1-97308; Novus Biologicals, Littleton, CO), anti-Flag (catalog no. F1804; Sigma-Aldrich), or antiKi67 antibody (catalog no. ab66155; Abcam, Cambridge, UK). Sections analyzed for GLP-1R and Flag were subsequently incubated with Alexa Fluor 488 goat anti-rabbit immunoglobulin (Ig)G (catalog no. A-11008; Thermo Fisher Scientific, Rockford, IL), and sections analyzed for Ki67 were subsequently incubated with Alexa Fluor 546 goat anti-rabbit IgG (catalog no. A-11010; Thermo Fisher Scientific). Sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and visualized with confocal microscopy.
5-bromo-2
0 -deoxyuridine assays
To evaluate cell proliferation in breast cancer cells, the 5-bromo-2 0 -deoxyuridine (BrdU) incorporation assay was performed using Cell Proliferation enzyme-linked immunosorbent assay (ELISA) kits (catalog no. 1647229; Roche Applied Science, Mannheim, Germany). Briefly, three kinds of breast cancer cells were plated at 5000 cells/well in 96-well culture plates in complete media. After attaining 60% to 70% confluence, cells were treated with media containing 10% FBS with or without Ex-4 (0.1 to 10 nM), and with or without linagliptin (0.1 to 10 nM) for 24 or 48 hours. BrdU solution (10 mM) was added during the last 2 hours of stimulation. Next, the cells were dried and fixed, and the cellular DNA was denatured with FixDenat solution (Roche Applied Science, Pleasanton, CA) for 30 minutes at room temperature. A peroxidase-conjugated mouse anti-BrdU monoclonal antibody (Roche Applied Science, Pleasanton, CA) was added to the culture plates, and the cells were incubated for 90 minutes at room temperature. Finally, tetramethylbenzidine substrate was added, and the plates were incubated for 15 minutes at room temperature, and the absorbance of the samples was measured using a microplate reader at 450 to 620 nm. Mean data are expressed as a ratio to control (nontreated) cell proliferation.
Apoptosis assays
For labeling nuclei of apoptotic cells, 1.2 3 10 5 breast cancer cells were plated on glass coverslips in Laboratory-Tek Chamber Slides (catalog no. 177380; Nunc, Thermo Scientific, Waltham, MA) and fixed in 4% paraformaldehyde for 25 minutes. Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) staining was performed using a DeadEnd Fluorometric TUNEL System (Promega, Madison, WI) according to the manufacturer's protocol. During the final 24 hours, cells were incubated with 10 nM Ex-4. Cells treated with 1 U/100 mL RQ1 RNase-Free DNase (catalog no. M6101; Promega) for 24 hours were used as a positive control.
Small interfering RNA knockdown of GLP-1R expression and cell proliferation assay
To knockdown GLP-1R, we used Stealth RNAi Pre-Designed small interfering RNA (siRNA) (Invitrogen, Carlsbad, CA), which was designed to target human GLP-1R (catalog no. HSS104179-81). Stealth RNAi Negative Control Duplexes (Invitrogen) were used as a negative control. For transfection, MCF-7 cells were plated at 2 3 10 5 cells/well in six-well plates and transfected with 10 nmol/L of siRNA targeting GLP-1R or negative control siRNA using MISSION siRNA Transfection Reagent (Sigma-Aldrich). Seventy-two hours after transfection, cells were subjected to the cell proliferation assay. Briefly, cells were detached and replated in 24-well tissue culture plates in complete media with or without 10 nM Ex-4. Forty-eight hours after treatment, cells were collected and counted using a hemocytometer. The siRNA knockdown efficiency was confirmed by RT-PCR and immunohistochemical analysis of GLP-1R.
Determination of cyclic adenosine monophosphate concentration
Measurement of cyclic adenosine monophosphate (cAMP) concentration was performed as described previously (11). Briefly, MCF-7 cells were plated in 96-well plates at 1.5 3 10 4 cells/well and cultured overnight. Next, cells were serum-deprived for 24 hours and incubated with saline (control) or 10 nM Ex-4 for 0, 15, 30, or 60 minutes. After incubation, the medium was aspirated and lysis buffer was added. Intracellular cAMP concentration was determined using a cAMP Enzyme Immunoassay Kit (Cyman Chemical, Ann Arbor, MI) according to the manufacturer's instructions.
Insulin measurements
Insulin concentrations in mouse serum were measured using an Ultra Sensitive Mouse Insulin ELISA Kit (Morinaga Institute of Biological Science, Inc., Kanagawa, Japan) according to the manufacturer's protocol.
Detection of NF-kB nuclear translocation
MCF-7 cells were plated at 3 3 10 5 cells/plate in 60-mm culture plates in complete media. After attaining 60% to 70% confluence, cells were treated with media containing 10% FBS with or without 10 nM Ex-4 for 0, 15, 30, or 60 minutes. The nuclear protein extracts were isolated from MCF-7 cells using a Nuclear Extraction Kit (catalog no. NBP2-29447; Novus Biologicals). NF-kB p65 content was determined using an ELISA kit (catalog no. NBP2-31042; Novus Biologicals). These procedures were performed according to the manufacturer's instructions. To evaluate GLP-1R inhibition of NF-kB p65 in breast cells, MCF-7 cells were pretreated for 30 minutes with or without 100 nM exendin (9-39), then treated with or without 10 nM Ex-4 for 15 minutes. After treatment, nuclear extraction and measurement of NF-kB p65 were performed as described above.
IL-8, VEGF, and COX-2 measurements
MCF-7 cells were plated at 1 3 10 5 cells/well in six-well culture plates in complete media. After attaining 60% to 70% confluence, cells were treated with media containing 10% FBS with saline (control) or 10 nM Ex-4 for 72 hours. Seventy-two hours after treatment, media were collected, and IL-8, VEGF, and COX-2 concentrations in the media were measured using the following ELISA kits: Human CXCL8/IL-8 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN), Human VEGF Quantikine ELISA Kit (R&D Systems), and Human COX-2 ELISA Kit (RayBiotech, Norcross, GA).
Plasmids, transient transfections, and luciferase assays
To evaluate NF-kB activation, luciferase reporter assays were performed in MCF-7 cells transiently transfected with pGL3-MMTV or pNF-kB-LUC reporter constructs, as described previously (16) . Briefly, MCF-7 cells were transfected with 0.5 mg of reporter DNA using FuGENE HD Transfection Reagent (Roche, Mannheim, Germany). Next, cells were maintained in media containing 10% FBS with saline (control) or 10 nM Ex-4 for 24 hours. Luciferase activity was assayed using the Dual-Luciferase Reporter Assay (Promega). Transfection efficiency was normalized to Renilla luciferase activity generated by cotransfection of cells with 10 ng/well pRL-SV40 (Promega).
Western blot analysis
Western blotting was performed as described previously (17 
Statistical analysis
Unpaired t tests, one-way analysis of variance (ANOVA), and two-way ANOVA for repeated measures were performed for statistical analysis as appropriate. P values less than 0.05 were considered statistically significant. Results are expressed as mean 6 standard error of the mean.
Results
GLP-1R is expressed in human breast cancer
To examine whether GLP-1R is expressed human breast cancer tissue, we first conducted immunohistochemical analysis of breast cancers obtained from patients who did not have diabetes. As depicted in Fig. 1A , typical ductal structure was observed by hematoxylin and eosin staining. Immunohistochemical staining for GLP-1R revealed obvious membrane-localized GLP-1R expression in human breast cancer tissue (Fig. 1A) . GLP-1R staining representative of that observed in breast cancer tissues from three independent patients is depicted in Fig. 1A . To further examine GLP-1R expression in human breast cancer cell lines, we performed immunohistochemical staining for GLP-1R in three breast cancer cell lines: MCF-7, which exhibits highly estrogen-sensitive proliferation; MDA-MB-231, which exhibits estrogenindependent proliferation; and KPL-1, which exhibits low sensitivity to estrogen. As shown in Fig. 1B , GLP-1R was abundantly expressed in the breast cancer cell lines, as well as in LNCaP prostate cancer cells, in which we have previously detected GLP-1R expression (11) . When we counted GLP-1R-positive cells and corrected for DAPI-positive cells, GLP-1R expression levels in MCF-7 and KPL-1 cells were not as high as those in LNCaP cells. However, GLP-1R was highly expressed in MDA-MB-231 cells, at a level comparable with that in LNCaP cells. On the basis of our previous report (11), we next performed RT-PCR on the 890-base pair coding sequence of GLP-1R to confirm expression of the GLP-1R gene. GLP-1R mRNA was abundantly expressed in MCF-7 cells, but expression levels were lower in MDA-MA-231 and KPL-1 cells (Fig. 1C) . The sequence of the PCR product was compatible with that of human GLP-1R complementary DNA as tested by direct sequencing (data not shown). Quantitative real-time RT-PCR analysis revealed that GLP-1R expression levels were significantly lower in breast cancer cell lines than in LNCaP cells. Among the three breast cancer cell lines, the highest GLP-1R gene expression level was detected in MCF-7 cells (Fig. 1D) . To confirm that GLP-1R expression is exclusively localized to the breast cancer cell membrane, and not to the cytosol or nucleus, we constructed a GLP-1R-expressing lentiviral vector containing a Flag epitope tag and transfected it into MCF-7 cells. Whereas immunohistochemical staining of GLP-1R revealed a small amount of immunofluorescence that was not located in the membrane fraction, probably because of limited antibody specificity, immunohistochemical staining of Flag was completely localized to the membrane (Fig. 1E) . These data suggest that GLP-1R is expressed in the breast cancer cell membrane in both human breast cancer tissue and cell lines.
Ex-4 attenuated breast cancer cell proliferation but did not induce apoptosis
We next examined the effect of Ex-4 on breast cancer cell number using a growth curve. Treatment with 0.1 to 10 nM Ex-4 significantly decreased the number of MCF-7, MDA-MB-231, and KPL-1 cells in a dose-dependent manner ( Fig. 2A-2C ). We next examined the mechanism through which Ex-4 decreased the number of breast cancer cells. First, we performed BrdU incorporation assays to assess DNA synthesis. Ex-4 treatment of 24 hours significantly decreased DNA synthesis in all three breast cancer cell lines in a dose-dependent manner (Fig. 2D-2F ). However, treatment with 10 nM Ex-4, the highest Ex-4 dose used in our experiments, did not induce TUNEL-positive apoptotic cells. In contrast, TUNELpositive cells were observed following DNase treatment as a positive control in MCF-7 cells (Fig. 2G) . The same results were also observed in MDA-MB-231 and KPL-1 cells (data not shown). These data suggest that Ex-4 attenuates breast cancer cell proliferation but does not induce apoptosis. To further examine the antibreast cancer effect of incretin therapy, we investigated the effect of a DPP-4 inhibitor, linagliptin, on breast cancer cell proliferation. However, linagliptin had no effect on breast cancer cell proliferation (Fig. 2H and 2I ).
Ex-4 attenuates breast cancer cell proliferation through GLP-1R activation
Because the most abundant GLP-1R gene expression was observed in MCF-7 cells, we used this cell line for subsequent experiments. The antiproliferative effect of Ex-4 was completely reversed by the GLP-1R antagonist exendin (Fig. 3A) . Additionally, GLP-1R knockdown using siRNA abolished the reduction in MCF-7 cell number by Ex-4 (Fig. 3B) , suggesting that the reduction in breast cancer cell number by Ex-4 occurred through GLP-1R activation. To confirm the substantial reduction of GLP-1R by the siRNA targeting GLP-1R, we conducted RT-PCR of the 890-base pair GLP-1R open reading frame and immunohistochemistry. As shown in Fig. 3C and 3D, GLP-1R was specifically and completely knocked down by the siRNA targeting GLP-1R. Because breast cancer cell proliferation partially depends on aromatase activity and elevated estrogen production by adipose tissue, we next examined whether the antiproliferative effects of Ex-4 were caused by decreased aromatase action in MCF-7 cells. Surprisingly, as shown in Fig. 3E , Ex-4 treatment significantly stimulated expression of the aromatase gene CYP19. Downstream of the GLP-1R canonical pathway, cAMP and PKA activation occur. In MCF-7 cells, Ex-4 increased intracellular cAMP concentrations rapidly and significantly compared with control (Fig. 3F) . These data suggest that GLP-1R is functionally intact in MCF-7 cells, and Ex-4 attenuates breast cancer cell proliferation through GLP-1R activation, regardless of aromatase activity.
Ex-4 attenuates breast cancer growth in vivo
To examine the antibreast cancer effect of Ex-4 in vivo, we transplanted MCF-7 cells into athymic nude mice. Nine weeks after subcutaneous transplantation of MCF-7 cells into the flank region of mice, tumor formation was observed, and tumor size was found to be decreased in Ex-4-treated mice (Fig. 4A) . Calculation of tumor size using the modified ellipsoid formula revealed that Ex-4 significantly decreased tumor size to almost half that of the control (Fig. 4B) . As shown in Fig. 4C and 4D , body weight and blood glucose levels were not changed following Ex-4 treatment. Compared with control, serum insulin levels were modestly increased in Ex-4-treated mice (control: 0.36 6 0.05 ng/mL vs Ex-4: 0.44 6 0.07 ng/mL), although this effect was not statistically significant (P = 0.18) (Fig. 4E) . Immunohistochemical analysis of paraffin-embedded sections of subcutaneous breast cancer tumors demonstrated that Ki67, a marker of cell proliferation and cell cycle progression, was clearly localized to the nucleus. Furthermore, Ki67 expression was dramatically and significantly decreased by Ex-4 treatment (Fig. 4F ). To further demonstrate that Ex-4 attenuates breast cancer growth via activation of GLP-1R in vivo, we treated mice with Ex-4 and with or without exendin (9-39), a GLP-1R antagonist. As shown in Fig. 4G , the reduction in Ki67 mRNA expression was significantly enhanced by combined treatment with Ex-4 and exendin (9-39), with expression levels reduced to control levels. These data suggest that Ex-4 attenuates breast cancer growth through inhibition of cell proliferation in vivo. Additionally, immunohistochemical staining of Ki67 and counting of Ki67-positive cells in mouse subcutaneous breast cancer tumors revealed that the Ex-4-induced decrease in Ki67-positive cell number was significantly canceled by combined treatment with , and (C) KPL-1 breast cancer cell lines were maintained in media supplemented with 10% FBS with saline or Ex-4 (0.1 to 10 nM). After 0, 24, 48, and 72 hours, the cells were harvested and cell proliferation was analyzed by cell counting using a hemocytometer. Black circles with solid line, control (nontreated; saline); black squares with dotted line, Ex-4 (0.1 nM); white circles with solid line, Ex-4 (1 nM); white squares with dotted line, Ex-4 (10 nM). Unpaired t tests were performed to calculate statistical significance (*P , 0.05 vs control; **P , 0.01 vs control) (n = 3). (D) MCF-7, (E) MDA-MB-231, and (F) KPL-1 cells were plated at 5000 cells/well in 96-well plates in media supplemented with 10% FBS, and incubated with Ex-4 (0 to 10 nM) for 24 hours. BrdU solution was added during the last 4 hours, and cells were harvested for measurement of DNA synthesis using a microplate reader to measure absorbance at 450 to 620 nm. Mean data are expressed as a ratio of control cell proliferation. Unpaired t tests were performed to calculate statistical significance (*P , 0.05 vs control; **P , 0.01 vs control) (n = 3). (G) MCF-7 cells were plated on glass coverslips in six-well plates. After incubation with 10 nM Ex-4 or 1 U/100 mL RQ1 DNase for 24 hours, apoptotic cells were detected with TUNEL staining. Images shown are representative of triplicate independent experiments. (H) MCF-7 cells were maintained in media supplemented with Ex-4 and exendin (Fig. 4H) . These data suggest that Ex-4 attenuates breast cancer growth via GLP-1R activation in vivo, independent of its effects on glucose metabolism.
Ex-4 inhibits NF-kB activation in breast cancer cells
Finally, we examined the molecular mechanism through which Ex-4 attenuates breast cancer cell proliferation. NF-kB is constitutively activated in cancers, including breast cancer, and contributes to cancer cell survival and cancer development (18) . Therefore, we examined whether Ex-4 attenuates NF-kB activation in MCF-7 cells. As shown in Fig. 5A , Ex-4 significantly inhibited NF-kB (p65) translocation into the nucleus during the early phase of Ex-4 treatment. The inhibitory effect of Ex-4 on NF-kB activation was completely abolished by the GLP-1R antagonist exendin (9-39) (Fig. 5B) , suggesting that inhibition of NF-kB nuclear translocation and transactivation were induced by GLP-1R activation. Furthermore, in a luciferase assay using the NF-kB response element, 24-hour incubation increased NF-kB transactivation in both saline (control) and Ex-4-treated cells; however, the extent of transactivation was significantly lower in Ex-4-treated cells than in control cells, suggesting that transactivation of the promoter containing the NF-kB binding site was inhibited by Ex-4 (Fig. 5C ). We next investigated gene expression of NF-kB target genes in breast cancer cells treated with Ex-4. IL-8, VEGF, and COX-2 are target genes of NF-kB in breast cancer. These genes play important roles in processes involved in breast cancer development, such as inflammation and angiogenesis (18) . As shown in Fig. 5D , whereas IL-8 gene expression was dramatically increased in saline-treated control cells, Ex-4 treatment significantly inhibited gene expression. Additionally, VEGF and COX-2 mRNA expression were also significantly attenuated by Ex-4 treatment, compared with control ( Fig. 5E and 5F ). To confirm the reduction of target gene expression by Ex-4 treatment, we next performed ELISA assays using conditioned media from MCF-7 cells treated with or without Ex-4 to assess protein levels. As shown in Fig. 5G and 5H, both IL-8 and VEGF production by MCF-7 cells were significantly decreased by Ex-4 treatment. Unfortunately, COX-2 protein expression levels were too low to be detected by ELISA (data not shown). Because transactivation and nuclear translocation of NFkB are regulated by IkBa phosphorylation, we next performed western blotting to examine IkBa phosphorylation. As depicted in Fig. 5I , Ex-4 reduced phosphorylated IkBa levels after 15 minutes of treatment. Furthermore, Akt, a kinase that phosphorylates IkBa and transactivates NF-kB, was dephosphorylated and inactivated by Ex-4 treatment in MCF-7 cells over the same time course as IkBa dephosphorylation (Fig. 5J) . These data suggest that Ex-4 could attenuate breast cancer cell proliferation through inhibition of NF-kB activation and subsequent reduction of target gene expression.
Discussion
In the current study, we demonstrated that GLP-1R was expressed in human breast cancer tissue and cell lines and that the GLP-1R agonist Ex-4 attenuated breast cancer growth by inhibiting NF-kB activation both in vivo and in vitro. Recently, incretin therapies, which include GLP-1R agonists and DPP-4 inhibitors, have become popular antidiabetic treatments throughout the world (19) , including in Japan (20) . There are many benefits of incretin therapy, such as pancreatic b-cell preservation, lower risk of weight gain, and fewer hypoglycemic attacks (21) . Additionally, incretin treatment is a therapeutic option for T2DM even during end-stage renal disease (22) . Furthermore, incretin therapies are expected to have tissue-protective effects beyond those associated with their glucose-lowering capacity (1) . However, the current considerable interest in incretin therapies has raised the issue of their long-term safety, including the risk of carcinogenesis.
GLP-1 action in cancer is controversial, as we discussed in a previous review (13) . Continuous exposure to liraglutide, a GLP-1R agonist, was associated with a marked increase in plasma calcitonin levels and thyroid C-cell hyperplasia in wild-type mice but not in GLP-1R-deficient mice (23) . Furthermore, GLP-1R expression has been detected in human neoplastic hyperplastic lesions of thyroid C cells (24) . Thus, it can be speculated that these reports warn of a risk of carcinogenesis associated with incretin therapies. In contrast, another study demonstrated an anticolon cancer effect of the GLP-1R agonist Ex-4 (25) , similar to that demonstrated in our study. Specifically, Ex-4 was shown to increase intracellular cAMP levels and inhibit glycogen synthase kinase 3 and ERK-MAPK activation, which led to decreased colony formation and augmented apoptosis induced by irinotecan, a topoisomerase Figure 2 . (Continued). 10% FBS containing dimethyl sulfoxide (control) or linagliptin (0.1 to 10 nM). After 48 hours, the cells were harvested, and cell proliferation was analyzed by cell counting using a hemocytometer. Unpaired t tests were performed to calculate statistical significance (**P , 0.01 vs 0 hours) (n = 3). (I) MCF-7 cells were plated at a density of 5000 cells/well in 96-well plates in media supplemented with 10% FBS, and incubated with linagliptin (0.1 to 10 nM) for 48 hours. BrdU solution was added during the last 4 hours, and cells were harvested for measurement of DNA synthesis using a microplate reader at 450 to 620 nm. Mean data are expressed as a ratio of control (nontreated) cell proliferation. Unpaired t tests were performed to calculate statistical significance (n = 3). . After 0, 24, 48, and 72 hours, the cells were harvested, and cell proliferation was analyzed by cell counting using a hemocytometer. Black circles with solid line, control (nontreated); black squares with dotted line, Ex-4 (10 nM); white circles with solid line, exendin (9-39) (100 nM); white squares with dotted line, Ex-4 (10 nM) + exendin (9-39) (100 nM). Unpaired t tests were performed to calculate statistical significance (*P , 0.05 vs control; **P , 0.01 vs control) (n = 3). (B) MCF-7 cells were transfected with either negative control duplexes or siRNA targeting GLP-1R and maintained in media with 10% FBS with saline or 10 nM Ex-4. After 0 or 72 hours, the cells were harvested, and cell proliferation was analyzed by cell counting using a hemocytometer. Unpaired t tests were performed to calculate statistical significance (**P , 0.01 vs control without Ex-4) (n = 3). I inhibitor, in CT26 murine colon cancer cells (25) . Additionally, our previous two studies demonstrated an antiprostate cancer effect of the GLP-1R agonist Ex-4 by inhibition of ERK-MAPK activation both in vivo and in vitro using a similar procedure to the current study (11) . Furthermore, we demonstrated an additional reduction in prostate cancer growth by combined Ex-4 and metformin therapy (12) . Interestingly, our findings are supported by the results of a recent large-scale clinical trial (26) , the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which used the GLP-1R agonist liraglutide. The primary end point of this trial was a reduction in cardiovascular events. However, in the supplemental appendix, it was reported that the GLP-1R agonist liraglutide significantly decreased prostate cancer compared with the placebo group with a hazard ratio of 0.54. Furthermore, no cancer incidences were significantly increased by liraglutide (26) . These data suggest that GLP-1 action might inhibit prostate cancer, and that no cancers are initiated or accelerated by GLP-1 action. Although we clearly detected membrane localized GLP-1R expression in human breast cancer tissue and cell lines (Fig. 1) , the GLP-1R agonist liraglutide did not reduce breast cancer risk in the LEADER trial (26) . In the current study, we recruited nondiabetic patients with breast cancer; however, in contrast, the LEADER trial enrolled patients who had T2DM. Therefore, some differences in findings might be related to the different disease background in patients. Further elucidation regarding the antibreast cancer effect of GLP-1R agonist is required. In the current study, Ex-4 inhibited NF-kB activation in breast cancer cells. NF-kB is one of the most important transcription factors not only in inflammatory diseases, but also in metabolic diseases, such as T2DM (27) . Recently, T2DM has been recognized as an inflammatory disease whose pathological characteristics include macrophage and T-cell infiltration into adipose tissue (28) . Accordingly, inhibition and knockdown of inflammatory chemokines resulted in a reduction in blood glucose levels, as we previously reported using a knockout mouse model lacking the chemokinelike protein osteopontin (29) . Furthermore, it has been reported that inhibition of NF-kB activation resulted in glucose-lowering effects. Salsalate, a nonsteroidal anti-inflammatory drug, has been reported to improve both insulin sensitivity (30) and insulin secretion (31) , and glucose tolerance was subsequently improved. Additionally, chronic activation of NF-kB by overexpression of IkB kinase-b in liver resulted in systematic insulin resistance (32) . Furthermore, NF-kB is one of the key regulators of diabetic vascular complications (33) . Indeed, previous reports have revealed inhibition of NF-kB activation by the GLP-1 and GLP-1R agonists liraglutide and Ex-4 in cell and animal models, including a cognitive dysfunction model (34) , a cardiac fibrosis model (35) , a pulmonary fibrosis model (36) , the pancreatic b-cell MIN6 line (37) , endothelial cells (38) , and vascular smooth muscle cells (39) . In our previous study, we also demonstrated that Ex-4 inhibited NF-kB nuclear translocation in macrophages; this was one of the molecular mechanisms by which the GLP-1R agonist reduced atheroma formation in apoE-deficient mice (4). In the current study, we demonstrated inhibition of NFkB transactivation and reduction of target gene expression by a GLP-1R agonist (Fig. 5) . In addition to metabolic diseases, NF-kB is also a key regulator of cancer biology (40) . Taken together, these findings suggest that NF-kB inhibition by GLP-1R agonists might be effective not only against metabolic disease, but also against cancer development.
Including our previous study (11, 12) , the exclusive membrane localization of GLP-1R has not been confirmed by immunohistochemistry in previously performed experiments, because the antibody to GLP-1R lacks sufficient sensitivity for this methodology. In the current study, we confirmed the membrane localization of GLP-1R using a lentiviral vector containing a Flag epitope (Fig. 1E) . This system revealed that Ex-4 acted through GLP-1R that was exclusively located in the cell membrane. Furthermore, this system might be useful for overexpression experiments of GLP-1R in future studies. In both in vivo (Fig. 3A) and in vitro (Fig. 4G and 4H ) experiments, the antiproliferative effect of Ex-4 on breast cancer was inhibited by the GLP-1R antagonist exendin or by knocking down GLP-1R (Fig. 3B) . These data suggest that the antibreast cancer effect of Ex-4 is mediated directly by activating GLP-1R expressed in breast cancer cell membranes. Unfortunately, the DPP-4 inhibitor linagliptin did not attenuate breast cancer cell proliferation, probably because GLP-1R activation was lower than when a GLP-1R agonist was used. However, a retrospective cohort study reported that DPP-4 inhibitors . Ex-4 inhibits NF-kB (p65) translocation into the nucleus and its transcriptional activity via GLP-1R. MCF-7 cells were treated with saline (control) or 10 nM Ex-4 diluted in media containing 10% FBS for 0, 15, 30, and 60 minutes. Nuclear protein extracts were then isolated from MCF-7 cells. NF-kB p65 levels were determined by ELISA [*P , 0.05 vs control (nucleus)] (n = 3). (B) MCF-7 cells were treated with or without 10 nM Ex-4 for 15 minutes and pretreated for 30 minutes with or without 100 nM exendin . Nuclear extraction and NF-kB p65 measurement were then performed as described above. Unpaired t tests were performed to calculate statistical significance [*P , 0.05 vs control (nucleus)] (n = 3). (C) MCF-7 cells were transiently transfected with pGL3-TK-NF-kB and maintained in media containing 10% FBS with saline (control, white bar, n = 3) or 10 nM Ex-4 (black bar, n = 3) for 24 hours. Luciferase activity was then measured. Transfection efficiency was adjusted by normalizing firefly luciferase activity to Renilla luciferase activity. Unpaired t tests were performed to calculate statistical significance (*P , 0.05 vs control; ## P , 0.01 vs 0 hours). MCF-7 cells were treated with saline (control, white bar, n = 3) or 10 nM Ex-4 (black bar, n = 3) diluted in media containing 10% FBS for 0, 3, 6, 12, and 24 hours. RNA was isolated and quantitative RT-PCR was performed to examine the expression of (D) IL-8, (E) VEGF, and (F) COX-2 mRNA. Unpaired t tests were performed to calculate statistical significance (*P , 0.05, **P , 0.01 vs control; # P , 0.05, ## P , 0.01 vs 0 hours). (G) IL-8 and (H) VEGF protein levels secreted into the culture medium were assayed by ELISA. Unpaired t tests were performed to calculate statistical significance (*P , 0.05 vs control) (n = 3). MCF-7 cells maintained in media containing 10% FBS were stimulated with 10 nM Ex-4 or saline (control) for 0, 5, 10, 15, 30, and 60 minutes. Cell lysates were harvested and subjected to western blotting to assess (I) phosphorylated Akt (Thr-308)/Akt and (J) phosphorylated IkBa/IkBa expression. might reduce breast cancer risk in Taiwanese women with T2DM (41) . Therefore, the antibreast cancer effect of DPP-4 inhibitors requires further elucidation.
Prior to our present study, two studies from other groups suggested antibreast cancer effects of the GLP-1R agonist Ex-4 (42, 43) . Similar to our present study, both studies used MCF-7 cells. In contrast to our study, however, they observed apoptosis in MCF-7 cells, whereas we did not. The discrepancy between our results and these previous reports might be explained by different Ex-4 doses. Previous reports treated MCF-7 cells with a much higher dose of Ex-4 (in the order of micromoles) than our study (in the order of nanomoles). We chose this dose on the basis of our previous study in prostate cancer cells (11) . Furthermore, data from studies in humans indicate that the dose of Ex-4 that we used in vivo and in vitro is comparable with clinical pharmacological doses (44) .
In conclusion, we detected GLP-1R expression in human breast cancer tissue and cell lines and demonstrated that Ex-4, a GLP-1R agonist, attenuated breast cancer by inhibiting NF-kB activation and target gene expression.
